Albert Lung advises companies throughout the United States and the Asia-Pacific region on capital market transactions, corporate governance, and securities laws. His clients, consisting primarily of publicly listed companies in emerging technology, biotechnology, software, and life sciences fields, seek his counsel on compliance with US Securities and Exchange Commission (SEC) regulations and disclosure requirements, New York Stock Exchange (NYSE) and NASDAQ listing requirements, corporate governance, and a variety of other general corporate matters.
Within the United States, Albert represents companies spanning an array of industries, particularly emerging technology and life sciences companies in Silicon Valley, as they accelerate their growth through venture financing transactions, private placements and public offerings, mergers and acquisitions (M&A), and other business transactions. He has experience in guiding investment banks and major stakeholders through initial public offerings (IPOs), follow-on and secondary offerings, private investment in public equity (PIPEs), Rule 144A offerings, and convertible debt financing.
Companies in the Asia-Pacific region that are looking for financing from US-based corporations seek Albert’s counsel on navigating complex securities law issues associated with cross-border financing. His understanding of US securities law and disclosure requirements allows him to find the most efficient ways for clients to raise funds from inside the United States.
He has served as the managing editor for the Cardozo Law Review in New York and authored the article, “Must-Carry Rules in the Transition to Digital Television: A Delicate Constitutional Balance.”
New York University, 1998, B.A., Summa Cum Laude
Yeshiva University, Benjamin N. Cardozo School of Law, 2001, J.D., Magna Cum Laude